Prognostic Stage IIA Breast Cancer AJCC v8 Completed Phase 2 Trials for Mirvetuximab soravtansine (DB12489)

Also known as: Prognostic Stage 2A Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0109633 (Prognostic Stage IIA Breast Cancer AJCC v8)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106077Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerTreatment